Drug intelligence / Profile preview

AMHR2 agonist

Development stage: Preclinical
Lead developer: Celmatix
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

AMHR2 agonist is an undisclosed preclinical **AMH analog** being developed by **Celmatix** as an injectable biologic for ovarian protection. The program is designed to **agonize Anti-M\u00fcllerian Hormone Receptor Type 2**, also known as **MISR2**, to modulate ovarian folliculogenesis and preserve ovarian reserve. Celmatix has described the lead indication as **chemotherapy induced ovarian failure**, with an initial clinical focus on preventing premature menopause in women undergoing chemotherapy; broader women's health applications have also been suggested. No specific molecular identifier, code name, or brand name has been publicly disclosed.

Other names: AMHR2 agonistAMHR-2 agonistAMHR 2 agonistAMH analog

Targets

AMHR2 (Anti-Müllerian hormone receptor type 2)

Beyond the preview

Go deeper on AMHR2 agonist.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMHR2 agonist.

Explore the full profile